Skip to main content

Table 2 Cohort Definitions

From: Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom

Cohort

Model Input

Value/Definition

Assumption

Poor Compliance

Mean age-at-KF (years)

15.40

Reported value in Nesterova, et al. (2015) [13]

Composite Compliance Score

21.93

Calculated using Nesterova’s equation [13]: 𝑦 = 0.30𝑥 + 8.82. Where \(y = 15.40\)

Treatment duration prior to KF (years)

13.40

Assumption: equal to the mean age-at-KF minus 2 years

Annual Compliance Score

1.62

Calculated based on treatment duration and CCS: 21.93 ÷ 13.40 = 1.62

Mean age-at-death (years)

48.77

Derived from survival analysis applied to Kaplan-Meier mortality data provided in Brodin-Sartorius et al. (2012) [8]; validated by clinical experts

Good Compliance

Mean age-at-KF (years)

23.00

Assumption: based on clinical expert guidance

Composite Compliance Score

47.27

Calculated using Nesterova’s equation [13]: 𝑦 = 0.30𝑥 + 8.82. Where \(y = 23.00\)

Treatment duration prior to KF (years)

21.00

Assumption: equal to the mean age-at-KF minus 2 years

Annual compliance score

2.25

Calculated based on treatment duration and CCS: 47.27 ÷ 21.00 = 2.25

Mean age-at-death (years)

56.37

Calculated by assuming the difference in mean age-at-KF between both cohorts is equal to the difference in mean age-at-death in both cohorts; validated by clinical experts

  1. LCL: leukocyte cystine level, CCS: Composite Compliance Score, KF: Kidney Failure, ACS: Annual Compliance Score